AIM: To analysis the clinical effect of Ranibizumab with laser photocoagulation for diabetic macular edema.

METHODS: Forty-two cases(72 eyes)of patients with diabetic macular edema collected from April 2014 to June 2015 in our hospital were randomly divided into observation group and control group. The observation group was given ranibizumab with laser photocoagulation therapy, and the control group was only given laser photocoagulation treatment. Macular edema subsiding, macular fovea retinal thickness change and vision improvement were compared between the two groups.

RESULTS: The total effective rate of the observation group was 94%, that of the control group was 78%, and the difference between the two groups was statistically significant(P<0.05). Before the treatment, macular foveal retinal thickness of the observation group was 486.58±85.26μm, that of the control group was 479.61±83.37μm, and the difference between the two groups was not statistically significant(P>0.05). At 3mo after treatments, the macular fovea retinal thickness of the observation group was 315.85±43.7μm that of the control group was 418.85±46.97μm. At 6mo after treatments, the macular fovea retinal thickness of the observation group and the control group was 245.58±25.67 and 369.85±36.48μm respectively, and the difference between the two groups was statistically significant(P<0.05). The vision improvement rates of the observation group and the control group were 78% and 50% respectively, and the difference between the two groups was statistically significant(P<0.05).

CONCLUSION: The treatment effect of ranibizumab with laser photocoagulation therapy for diabetic macular edema is remarkable, and recommended in clinical promotion.